Shilpa Medicare has been granted a patent for a stable oral liquid pharmaceutical composition containing vigabatrin, preservatives, and various agents, ensuring low impurity levels over three months at room temperature. The composition’s pH ranges from 5 to 8, enhancing its therapeutic efficacy. GlobalData’s report on Shilpa Medicare gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Shilpa Medicare, Nanoparticle drug conjugates was a key innovation area identified from patents. Shilpa Medicare's grant share as of July 2024 was 22%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12016857B2 outlines a liquid pharmaceutical composition primarily containing vigabatrin, or its pharmaceutically acceptable salts, in concentrations ranging from 0.1 wt % to 20 wt %. The composition is designed to include various additional components such as preservatives, buffering agents, sweeteners, flavoring agents, and optional excipients like solubilizers, antioxidants, and coloring agents. Notably, the formulation is stable for up to three months at room temperature, maintaining total impurities below 0.06% during this period. The claims specify that the composition can be free of polyhydric alcohols with 2 to 6 carbon atoms, ensuring a specific formulation profile.
Further claims detail preferred ingredients and their concentrations, including a more specific range for vigabatrin (5 wt % to 15 wt %), and suggest particular preservatives like methyl and propyl 4-hydroxy benzoate. The sweeteners and flavoring agents are also specified, with a wide variety of options including natural extracts and synthetic flavor oils. The composition is designed to have a pH between 5 and 8, ensuring compatibility with various therapeutic applications. The patent emphasizes the importance of maintaining the integrity and stability of the formulation, which is critical for effective pharmaceutical delivery.
To know more about GlobalData’s detailed insights on Shilpa Medicare, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.